Macroaxis: Personalized Investing
Simple Personalized Investing

SP 500   1,655   13.81  Index Moved Down -0.83%
BHP AGG CBA RIO Computers Silver Music and Video Hybrid Mix 
United States GSPC USD ...  |  Company Directory


Processing
Processing. Please wait...

Biota insider: Simon Tucker

       

Simon Tucker - Biota Insider Profile

VP of Research

Dr. Simon Tucker serves as Vice President of Research at Biota Holdings Ltd. He joined the Company in 1997. He has over 20 years of scientific and commercial experience in research and development. Prior to joining the Company, he held leadership positions at GD Searle and Universities of Alabama, the United States and Glasgow, the United Kingdom. He has experience in biotechnology and pharmaceutical research and development, intellectual property management, research and development alliance management, licensing and related areas.
        
61 3 9915 3700  http://www.biota.com.au

Other Appointments

Biota Holdings LtdBTAHYUnited States AMEX
President
Biota Holdings LtdBTAHFUnited States OTC
President
Biota Holdings LtdBTAHYUnited States OTC
President
Biota Holdings LtdBTAHFUnited States AMEX
VP

Management Efficency

The company has return on total asset (ROA) of (15.95) % which means that it has lost $15.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (27.83) % meaning that it generated substantial loss on money invested by shareholders.
    

Other Executives

Peter Cook, CEO
FRMIT, Pharm, CEO
James Fox, Chairman
Jane Ryan, President
Vivienne Green, President
GAICD, FCA, CFO
Damian Lismore, CFO
Ian Gust, Director
John Lambert, Director, Ph.D
Jeffery Errington, Director
Paul Bell, Director
Richard Hill, Director
Grad BA, VP
Leigh Farrell, VP, Ph.D
Jane (Hons), VP

Entity Summary

Biota Holdings Limited engages in the drug discovery and clinical development of antiinfectives in Australia. Biota Pharmaceuticals Inc [BTA] is traded on Australian Securities Exchange in Australia. It is located in Notting Hill, VIC and employs 15 people. Filter other
    
Specify Title
Indicate Tenure
Select Industry
Click to run this filter
 Run Equity Filter
Filter Other Insiders
 
    
    
BTA Australia Australian #AU000000BTA1AU
Biota Pharmaceuticals Inc
Benchmark S&P 500
Currency: AUD - Australian Dollar
Traded on Australian Securities Exchange
    
    
Chance of
Bankruptcy
More
Than
78%
In The Next
Two Years
Biota Pharmaceuticals Inc has more than 78.4 (%) percent chance of experiencing financial distress in the next 2 years of operations.
    
    

Promote Biota and Simon Tucker

Follow Biota with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Biota to your reader
 

Today Change

 thisGreen BTA BTA.AX agains markets  0.00 % No Change  
 
 United States SP 500   0.83 % Macroaxis: 0.83 Moved Down  
 
 Australia All Or   1.22 % Macroaxis: change 1.22 Moved Down  
 

Stock Performance

Shares Outstanding182.11 M


 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium